Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

Oct 5, 2023JAMA

Risk of Stomach and Digestive Problems Linked to Weight-Loss Drugs Acting on GLP-1 Receptors

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Full Text

Full text is available at the source.

View full text ↗

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

what lands in your inbox each week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

Semaglutide linked to 2.5x higher risk of sudden vision loss

3 days ago7 studies

Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial

1 week ago7 studies

Semaglutide linked to 53% lower risk of death in dialysis patients with diabetes

2 weeks ago7 studies

60% of weight lost on GLP-1 drugs returns within a year of stopping

3 weeks ago7 studies

Semaglutide linked to 54% lower risk of new sleep apnea cases in 1.25 million patients

4 weeks ago7 studies

Tirzepatide beats semaglutide for heart protection in 70,672 non-diabetic adults with obesity

5 weeks ago7 studies

Stopping GLP-1 drugs before endoscopy cuts stomach content risk from 25% to 3%

6 weeks ago7 studies

Semaglutide linked to 74-fold higher risk of vision-threatening eye condition

7 weeks ago3 studies

GLP-1 drugs linked to 18% lower risk of substance use disorders in 524,817 veterans

8 weeks ago7 studies

86.5% of patients on semaglutide or tirzepatide lost at least 5% of body weight at 6 months in Medicaid study

9 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief